KR20060094704A - Cosmetic composition containing collagenase inhibition and collagen synthesis promoting effect containing milk extract - Google Patents
Cosmetic composition containing collagenase inhibition and collagen synthesis promoting effect containing milk extract Download PDFInfo
- Publication number
- KR20060094704A KR20060094704A KR1020050016084A KR20050016084A KR20060094704A KR 20060094704 A KR20060094704 A KR 20060094704A KR 1020050016084 A KR1020050016084 A KR 1020050016084A KR 20050016084 A KR20050016084 A KR 20050016084A KR 20060094704 A KR20060094704 A KR 20060094704A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- cosmetic composition
- collagen
- hair
- scalp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000284 extract Substances 0.000 title claims abstract description 70
- 108010035532 Collagen Proteins 0.000 title claims abstract description 40
- 102000008186 Collagen Human genes 0.000 title claims abstract description 40
- 229920001436 collagen Polymers 0.000 title claims abstract description 35
- 239000000203 mixture Substances 0.000 title claims abstract description 27
- 239000002537 cosmetic Substances 0.000 title claims abstract description 20
- 230000015572 biosynthetic process Effects 0.000 title claims description 17
- 238000003786 synthesis reaction Methods 0.000 title claims description 15
- 230000001737 promoting effect Effects 0.000 title claims description 7
- 102000029816 Collagenase Human genes 0.000 title abstract description 16
- 108060005980 Collagenase Proteins 0.000 title abstract description 16
- 229960002424 collagenase Drugs 0.000 title abstract description 12
- 239000008267 milk Substances 0.000 title description 30
- 210000004080 milk Anatomy 0.000 title description 30
- 235000013336 milk Nutrition 0.000 title description 30
- 230000005764 inhibitory process Effects 0.000 title description 6
- 230000000694 effects Effects 0.000 claims abstract description 25
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 7
- 210000004761 scalp Anatomy 0.000 claims description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 6
- 239000002904 solvent Substances 0.000 claims description 6
- 238000000605 extraction Methods 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 150000001298 alcohols Chemical class 0.000 claims description 3
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 239000012049 topical pharmaceutical composition Substances 0.000 claims 1
- 108010038862 laminin 10 Proteins 0.000 abstract description 16
- 102000004190 Enzymes Human genes 0.000 abstract description 7
- 108090000790 Enzymes Proteins 0.000 abstract description 7
- 229940088598 enzyme Drugs 0.000 abstract description 7
- 238000001243 protein synthesis Methods 0.000 abstract description 6
- 230000014616 translation Effects 0.000 abstract description 6
- 210000003491 skin Anatomy 0.000 description 30
- 210000004209 hair Anatomy 0.000 description 28
- 238000011156 evaluation Methods 0.000 description 17
- 210000004027 cell Anatomy 0.000 description 15
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 12
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 12
- 230000000052 comparative effect Effects 0.000 description 11
- 210000002744 extracellular matrix Anatomy 0.000 description 11
- 238000005728 strengthening Methods 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 210000003780 hair follicle Anatomy 0.000 description 9
- 230000001965 increasing effect Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 238000011161 development Methods 0.000 description 8
- 230000018109 developmental process Effects 0.000 description 8
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 4
- 201000004384 Alopecia Diseases 0.000 description 4
- 102000016942 Elastin Human genes 0.000 description 4
- 108010014258 Elastin Proteins 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 210000004207 dermis Anatomy 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 208000024963 hair loss Diseases 0.000 description 4
- 230000003676 hair loss Effects 0.000 description 4
- 210000003128 head Anatomy 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000037394 skin elasticity Effects 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000000502 dialysis Methods 0.000 description 3
- 230000002500 effect on skin Effects 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000034756 hair follicle development Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000006180 TBST buffer Substances 0.000 description 2
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- 239000006143 cell culture medium Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000002316 cosmetic surgery Methods 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000004177 elastic tissue Anatomy 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000031774 hair cycle Effects 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229940079938 nitrocellulose Drugs 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 2
- 210000001626 skin fibroblast Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- AXAVXPMQTGXXJZ-UHFFFAOYSA-N 2-aminoacetic acid;2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound NCC(O)=O.OCC(N)(CO)CO AXAVXPMQTGXXJZ-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 108010027805 Azocoll Proteins 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 108050001049 Extracellular proteins Proteins 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 241000218220 Ulmaceae Species 0.000 description 1
- 241000949731 Ulmus davidiana Species 0.000 description 1
- 244000058281 Ulmus pumila Species 0.000 description 1
- 235000001547 Ulmus pumila Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229940076810 beta sitosterol Drugs 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000036569 collagen breakdown Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 102000034240 fibrous proteins Human genes 0.000 description 1
- 108091005899 fibrous proteins Proteins 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000001365 lymphatic vessel Anatomy 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 230000004660 morphological change Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- G—PHYSICS
- G08—SIGNALLING
- G08G—TRAFFIC CONTROL SYSTEMS
- G08G1/00—Traffic control systems for road vehicles
- G08G1/09—Arrangements for giving variable traffic instructions
- G08G1/095—Traffic lights
-
- G—PHYSICS
- G08—SIGNALLING
- G08G—TRAFFIC CONTROL SYSTEMS
- G08G1/00—Traffic control systems for road vehicles
- G08G1/07—Controlling traffic signals
- G08G1/075—Ramp control
-
- G—PHYSICS
- G08—SIGNALLING
- G08G—TRAFFIC CONTROL SYSTEMS
- G08G1/00—Traffic control systems for road vehicles
- G08G1/09—Arrangements for giving variable traffic instructions
- G08G1/096—Arrangements for giving variable traffic instructions provided with indicators in which a mark progresses showing the time elapsed, e.g. of green phase
Landscapes
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 화장료 조성물에 관한 것으로, 특히 콜라겐 단백질을 분해하는 콜라겐에이즈(Collagenase) 효소의 활성을 억제시킴과 동시에 콜라겐 단백질 합성을 촉진시키는 효과를 갖는 유백피 추출물을 함유한 화장료 조성물에 관한 것이다. The present invention relates to a cosmetic composition, and more particularly, to a cosmetic composition containing the milky skin extract having the effect of inhibiting the activity of the collagenase (Collagenase) enzyme that breaks down the collagen protein and promotes collagen protein synthesis.
유백피 추출물, 콜라겐에이즈, 라미닌-10, 화장료 Milky skin extract, collagen, laminin-10, cosmetics
Description
본 발명은 유백피 추출물을 함유하는 화장료 조성물에 관한 것이다. 더욱 구체적으로 본 발명은 유효성분으로서 콜라겐 단백질을 분해하는 콜라겐에이즈(Collagenase) 효소의 활성을 억제시킴과 동시에 콜라겐 단백질 합성을 촉진시키는 효과를 갖는 유백피 추출물을 함유한 것을 특징으로 한다. 또한,본발명의 유백피 추출물은 모낭 형성,발달에 필수요소인 라미닌-10 단백질의 발현을 촉진시켜, 튼튼한 모근을 유지하는데 효과를 보인다. The present invention relates to a cosmetic composition containing the milk extract. More specifically, the present invention is characterized in that it contains a milk extract containing the effect of inhibiting the activity of collagenase (Collagenase) enzyme that degrades collagen protein as an active ingredient and at the same time promotes collagen protein synthesis. In addition, the milk extract of the present invention promotes the expression of laminin-10 protein, which is essential for hair follicle formation and development, and is effective in maintaining strong hair roots.
피부는 표피와 진피로 구성되어 있는데, 진피에는 세포외기질(extracellular matrix:ECM)이 존재하여 탄력적인 성질을 갖는다. 이것은 무정형의 기질(glycosaminoglycans)과 여기에 박혀있는 교원질 및 탄력섬유 등의 섬유성 단백질로 구성되어 있다. 이들은 혈관계나 신경 그리고 림프관 등의 맥관계를 고정하는 기능을 하고 땀샘이나 피지선과 같은 표피부속기관을 지탱하는 역할을 한다. 특히 두피의 경우에는 모발이 존재하기 때문에, 두피의 세포외기질의 역할에는 모발을 지탱하는 임무가 추가적으로 존재하게 된다.The skin consists of the epidermis and the dermis. The dermis has an extracellular matrix (ECM), which is elastic. It consists of amorphous substrates (glycosaminoglycans) and fibrous proteins such as collagen and elastic fibers embedded in them. They function to fix the vascular system such as the vascular system, nerves and lymphatic vessels, and support the epidermal organs such as sweat glands and sebaceous glands. Especially in the case of the scalp, since the hair is present, the role of the extracellular matrix of the scalp is to additionally support the hair support.
피부는 노화됨에 따라서 세포외기질의 구조적인 변형이 유발된다. 대표적으로 콜라겐, 엘라스틴, 피브릴린 등과 같은 세포외기질의 구조적인 단백질들의 변화를 들 수 있다. 그 중 콜라겐의 경우 내인성 노화에 의해서 그 합성양이 감소하거나 변성되게 된다. 이는 피부주름 발생을 촉진하는 원인이 된다. 또한 탄력을 주는 탄력섬유의 수가 줄어들며 수직구성 되어있던 것이 수평으로 배열되는 형태적인 변형도 일어나게 된다. 이러한 형태적인 변화가 피부의 탄력성 감소에 중요한 영향을 미치는 것으로 알려져 있다. 따라서 부족한 세포외기질 분자들의 생성을 촉진하거나, 생성된 세포외기질 분자를 분해하는 효소들을 저해할 수 있는 물질들의 개발이 많이 이루어지고 있다. 두피의 경우에는 좀 더 특이적으로, 세포외기질을 구성하는 단백질 분포가 모낭의 발달과 직접적으로 연관 되어있다. 모낭의 경우, 모발 주기에 따라 표피에서 진피로 위아래로 조직이 이동하는 특징이 있다. 어떠한 원인에 의해 모낭 발달이 실패한 경우, 모발도 생성되지 않으며 결국엔 탈모로 진행된다. 한 예로, 세포외기질 구성성분인 라미닌-10의 경우, 모낭의 발달을 촉진하는 인자로 알려져 있으며, 탈모환자의 병변 부위에는 라미닌-10의 발현이 억제되고, 대신 라미닌이 과발현 되어있다고 밝혀져있다.As the skin ages, structural modification of the extracellular matrix is induced. Representative examples include changes in structural proteins of extracellular matrix such as collagen, elastin, and fibrin. Among them, collagen is reduced or denatured due to endogenous aging. This causes skin wrinkles to be promoted. In addition, the number of elastic fibers that give elasticity is reduced, and there is also a form deformation in which the vertical structure is arranged horizontally. These morphological changes are known to have an important effect on reducing the elasticity of the skin. Therefore, the development of substances capable of promoting the production of scarce extracellular matrix molecules or inhibit enzymes that degrade the extracellular matrix molecules produced. More specifically in the scalp, the distribution of proteins that make up the extracellular matrix is directly related to the development of hair follicles. Hair follicles are characterized by the movement of tissue up and down from the epidermis to the dermis, depending on the hair cycle. If hair follicle development fails for any reason, no hair is produced, eventually leading to hair loss. For example, laminin-10, an extracellular matrix component, is known to be a factor that promotes the development of hair follicles. Laminin-10 expression is suppressed at the lesion site of hair loss patients, and laminin is overexpressed.
한국 특허 제0163118호에 의하면, 유백피 추출물이 포함된 화장용 세정제 조성물이 양혈, 항균 및 수렴효과로 피부 및 두피 개선에 유효하다고 밝히고 있으나,According to Korean Patent No. 0163118, cosmetic cleansing composition containing the milk extract is effective in improving the skin and scalp by the amount of blood, antibacterial and astringent effects.
유백피 추출물의 어떠한 작용에 의해 그러한 효능을 나타내는지 구체적인 기전에 대하여는 전혀 기재된바 없다. 본 발명에서는 유백피 추출물이 콜라겐에이즈 활성 억제 및 콜라겐 합성 촉진 효능을 가지고 있으며, 모낭 발달에 중요한 성분인 라미닌-10의 발현을 촉진하여 정상적인 모낭 발달을 유도함으로써 두피의 탄력증진 및 모근 강화를 통해 노화 방지 효능이 있음을 분자 수준 및 임상평가에서 밝혀내었다.There is no description of the specific mechanism by which the effect of the milk extract is exhibited. In the present invention, the milk extract has the effect of inhibiting collagenase activity and promoting collagen synthesis and stimulating the expression of laminin-10, which is an important component for hair follicle development, inducing normal hair follicle development, thereby aging the skin by strengthening the elasticity and strengthening the hair root. It has been shown at the molecular level and in the clinical evaluation that there is an efficacy in prevention.
본 발명자들은 두피의 탄력 증대 및 모근강화 효과를 가지는 생약추출물 스크리닝을 위해, 인체에 대한 안전성이 확보된 식물추출물 수십 종을 선택하여 콜라겐에이즈 효소 억제와 콜라겐 합성을 촉진에 대한 평가를 실시한 결과 유백피 추출물을 발견 하였다. 또한, 유백피 추출물을 동물에 적용하여 평가를 하였을 때에도, 마우스 등조직 중 세포외기질 부분이 두터워지는 것을 조직염색을 통하여 확인하였다. The present inventors have selected dozens of plant extracts that have a safety for the human body to screen the herbal extracts having the effect of enhancing the elasticity of the scalp and strengthening the hair root, and evaluated the inhibition of collagenase enzymes and the promotion of collagen synthesis. An extract was found. In addition, it was confirmed through tissue staining that the extracellular matrix portion of the mouse's back tissue became thick even when the milky skin extract was applied to the animal and evaluated.
본 발명에 의한 화장료조성물은 유백피 추출물이 콜라겐에이즈 억제 및 콜라겐 합성촉진 이라는 명확한 작용기전을 가지며, 이에 따라 두피탄력을 증진시키는 효과를 가진다. 이러한 두피탄력 증대는 사람에게 적용하였을 때에도, 우수한 효과로 인지되었다. 뿐만 아니라, 유백피 추출물은 모낭조직의 발달을 촉진시키는 것으로 알려진 라미닌-10의 단백질 발현 평가에서도 우수한 결과를 나타내며, 실제 사람의 모발당겨보기 시험결과 모근 강화 효능을 확인하여 본 발명을 완성하게 되었다. The cosmetic composition according to the present invention has a clear mechanism of action that the milk extract extracts collagenase and promotes collagen synthesis, thereby enhancing scalp elasticity. This increase in scalp elasticity was recognized as an excellent effect even when applied to humans. In addition, the milk extract shows excellent results in the evaluation of the protein expression of laminin-10, which is known to promote the development of hair follicle tissue, and confirmed the hair root strengthening effect of the actual human hair pulling test to complete the present invention.
본 발명은 유효성분으로서 유백피 추출물을 고형분으로서 0.01~10중량%를 함유함을 특징으로 하는 콜라겐에이즈 억제 및 콜라겐합성 촉진, 모근강화 효능을 갖 는 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition having collagenase inhibition and collagen synthesis promotion, hair root strengthening effect, characterized in that it contains 0.01 to 10% by weight of the milky skin extract as an active ingredient.
본 발명 화장료조성물에 사용되는 유백피는 한국의 중부이북과 중국 및 일본에 각각 분포하는 느릅나무과 식물인 왕느릅나무(Ulmus macrocarpa), 비술나무( Ulmus pumila), 느릅나무(Ulmus davidiana) 의 줄기부분 또는 뿌리부분의 근피를 채취하여 햇볕에 말린 것으로, 약리작용으로 이수, 소종, 통림, 수종, 단독작용이 있는 있는 것으로 알려져 있으며, 주요성분으로는 베타시토스테롤(β-Sitosterol), 식물스테롤, 및 탄닌등으로 구성되어 있다.Yubaekpi used in the cosmetic composition of the present invention is the stem part of the elm family Ulm macrocarpa, Ulmus pumila, Ulmus davidiana, which are distributed in North Korea, China and Japan, respectively. The root part of the root is collected and dried in the sun, and pharmacological action is known to be diuretic, small seedling, canned, species, and independent action. The main ingredients are beta-sitosterol, phytosterol, and tannin. It consists of.
본 발명에 사용된 유백피추출물의 제조방법은 건조생약재를 음건 세절하고 분말화 시켜 가루 50g에 추출용매500ml를 가하여 3일간 침적추출 한 후, 그 추출물을 여과시킨 다음 감압 농축시킨후 본 발명에 사용하였다. 이때 사용한 추출 용매로는 그 선택에 있어서 특별히 한정되지는 않으나 정제수, 메탄올, 에탄올, 이소프로필알코올, n-부탄올 등의 저급알코올, 글리세롤, 프로필렌글리콜, 1,3-부틸렌글리콜 등의 다가알코올, 메틸아세테이트, 에틸아세테이트, 벤젠, n-헥산, 디에틸에테르, 디클로로메탄 등의 탄화수소계 용매 등을 예로 들 수 있다. 그러나 메탄올이나 에탄올, n-부탄올 등의 저급알코올을 추출 용매로 사용하는 것이 바람직하며, 이들 중에서 하나 또는 두 종류 이상의 용매를 혼합하여 추출에 사용할 수 있다.Milky skin extract used in the present invention is a dry herbal medicine is dried and finely pulverized and powdered to 50g of powder to extract the extraction solvent 500ml after extracting the extract for 3 days, the extract is filtered and then concentrated under reduced pressure and used in the present invention It was. Although the extraction solvent used at this time is not specifically limited in the selection, Polyhydric alcohols, such as lower alcohols, such as purified water, methanol, ethanol, isopropyl alcohol, n-butanol, glycerol, propylene glycol, 1, 3- butylene glycol, And hydrocarbon solvents such as methyl acetate, ethyl acetate, benzene, n-hexane, diethyl ether and dichloromethane. However, lower alcohols such as methanol, ethanol, and n-butanol are preferably used as extraction solvents, and one or two or more of them may be mixed and used for extraction.
제조예 : 유백피 추출물의 제조방법Preparation Example: Method of Preparing Milky Skin Extract
본 발명의 실시예에 사용된 유백피 추출물의 제조방법은 먼저 유백피의 뿌리를 세절하여 10호의 체를 통과한 가루50g에 대한약전품 에탄올 500ml을 가하여 3일간 실온에서 냉침하였다. 추출된 원액을 와트만 #1 여과지를 사용하여 여과하고 여 과된 추출물을 감압농축기를 이용하여 45℃에서 추출 용매를 완전히 증발시켜 건조된 추출물 2.5g을 얻었다.In the method of preparing the milk extract, the root of the milk extract was first chopped, and 500 ml of the medicinal product ethanol was added to 50 g of the powder passed through the sieve of No. 10, followed by cooling at room temperature for 3 days. The extracted stock solution was filtered using Whatman # 1 filter paper, and the filtered extract was evaporated completely at 45 ° C. using a vacuum condenser to obtain 2.5 g of the dried extract.
본 발명의 화장료조성물에 사용된 유백피 추출물의 함량은 조성물 전체중량 대비 고형분으로서0.01 ~ 10 중량%이며, 종합적인 두피 케어를 위해 피지조절제, 비듬 방지제, 각질 연화제, 청량제, 보습제, 항염증제 등의 보조성분들을 첨가 할 수 있다.The content of the milky skin extract used in the cosmetic composition of the present invention is from 0.01 to 10% by weight as a solid content relative to the total weight of the composition, and supplements such as sebum control agents, anti-dandruff agents, keratin softeners, softening agents, moisturizing agents, anti-inflammatory agents, etc. for comprehensive scalp care. You can add ingredients.
또한, 본 발명에서 예시된 세포실험에 사용된 유백피 추출물은 다음과 같이 준비하였다. 우선, 냉침 후 용매를 완전히 증발시켜 얻게된 고형분의 농도를 100중량%로 정의하고, 이를 세포에 적용하기 위하여 70% 에탄올을 사용하여 1중량 % stock 용액으로 희석해두었다. 이 추출물의 효능을 평가하는데 있어서, 세포에 독성이 없는 농도를 결정하기 위하여 0.000001중량% ~ 0. 1중량% 의 농도 범위에서 세포 독성 평가를 수행하였다. 그 결과, 0.001중량% 이상의 농도에서 세포 독성을 나타내어, 세포 적정 처리 농도는 0.000001중량% ~ 0.0001중량% 범위로 정하여 평가하였다.In addition, the milky skin extract used in the cell experiments exemplified in the present invention was prepared as follows. First, the concentration of the solid content obtained by completely evaporating the solvent after cooling was defined as 100% by weight, and diluted with 1% by weight stock solution using 70% ethanol to apply it to the cells. In evaluating the efficacy of this extract, a cytotoxicity assessment was performed in a concentration range of 0.000001% by weight to 0.01% by weight to determine the concentration without toxicity to the cells. As a result, the cytotoxicity was shown at a concentration of 0.001% by weight or more, and the cell titration treatment concentration was determined by setting it in the range of 0.000001% by weight to 0.0001% by weight.
<유백피 추출물의 콜라겐에이즈 활성 억제 평가 실험><Evaluation of Collagen Aid Inhibition of Milky Skin Extracts>
성형외과 두피 수술에서 얻은 사람의 두피 조직을 호모제나이저(Homogenizer) 로 분해한 후, 원심분리를 통해 상등액 만을 취한다. 그 상등액으로부터 세파아크릴(Sephacryl)S-200 크로마토그래피를 통하여 콜라겐에이즈를 순수 분리한다. 1.5ml 에펜돌프튜브(Eppendorf)에 2%의 적색 콜라겐기질인 아조콜 (Azocoll)용액 100㎕를 각각 첨가하여 한개의 에펜돌프튜브는 블랭크(Blank)로 사 용하고 나머지 튜브에는 시그마로부터 구입한 콜라겐에이즈 타입Ι인 표준 효소용액(콜라겐 분해활성도: 315 units/mg)을10, 100, 200ppm되게 첨가한다.Human scalp tissue obtained from plastic surgery scalp surgery is digested with a homogenizer, and only the supernatant is taken by centrifugation. The collagen is purely separated from the supernatant through Sephacryl S-200 chromatography. 100 ml of 2% red collagen substrate Azocoll solution was added to 1.5 ml Eppendorf, and one eppendorf tube was used as a blank and the other tube was obtained from Sigma. Add AIDS type I standard enzyme solution (collagen breakdown activity: 315 units / mg) to 10, 100 or 200 ppm.
튜브의 각 각에 앞서 분리해 둔 콜라겐에이즈 효소 100㎕를 첨가한 후, 한 개의 튜브는 대조군으로 사용하고 나머지 튜브의 각 각에 유백피 추출물을 0.000001중량% ~ 0.0001중량%의 농도로 증류수와 1:2의 비율로 혼합하여 완전히 균질화시켜 5000g에서 10분동안 원심분리시킨다. 원심분리 후, 상등액을 10㎕취하고, 완충용액(0.05M Tris-HCl, 1nM CaCl2, 7.8)을 총반응액이 500㎕되게 첨가하여 37℃ 항온기에서 18시간동안 반응시키고 에펜돌프튜브를 10000g에서 5분동안 원심분리하여 분해되지 않은 콜라겐은 침전시키고 분해된 콜라겐을 함유하는 상등액을 취하여 540nm에서 흡광도를 측정하여 표준활성도 곡선을 작성하고 표준 곡선으로부터 효소의 농도를 환산하여 실험군과 대조군의 효소활성도를 비교 평가하여 다음과 같은 결과를 얻었다. <표 1>After adding 100 µl of the collagenase enzyme isolated before each tube, one tube was used as a control, and each of the remaining tubes was diluted with distilled water and concentrated at a concentration of 0.000001% to 0.0001% by weight. Mix at a ratio of 2: 2 to fully homogenize and centrifuge at 5000 g for 10 minutes. After centrifugation, 10 µl of the supernatant was taken, buffer solution (0.05 M Tris-HCl, 1 nM CaCl 2, 7.8) was added to 500 µl of the total reaction solution, and reacted for 18 hours at 37 ° C. incubator at 10000 g. Undigested collagen was precipitated by centrifugation for 5 minutes, and the supernatant containing the degraded collagen was taken. The absorbance was measured at 540 nm to prepare a standard activity curve, and the enzyme concentration was converted from the standard and control groups. Comparative evaluation yielded the following results. TABLE 1
이상의 시험결과에서 제형에 관계없이 Collagenase활성에 대한 억제효과가 유백피 농도가 증가 함에 따라 상승되는 것으로 나타났다.In the above test results, the inhibitory effect on collagenase activity was increased with increasing the concentration of milky skin regardless of the formulation.
<유백피 추출물의 콜라겐 단백질 합성에 대한 효능 평가 실험><Efficacy Evaluation Experiments on Collagen Protein Synthesis of Milky Skin Extracts>
성형외과로부터 두피 수술 후 사람의 두피 조직을 얻어 이로부터 피부 섬유아세포(Skin Fibroblast)를 분리, 배양하였다.After scalp surgery from plastic surgery, human scalp tissues were obtained and skin fibroblasts were isolated and cultured therefrom.
24-Well plate에 106 cell/well 되도록 분주한 다음 10% FBS가 함유된 DMEM배지에서 하룻동안 배양한 다음날 기존의 배지를 신선한 배지로 교체하여 24시간 동안 배양한 후에 HBSS완충용액으로 바닥에 붙은 세포층을 세척한 다음 혈청과 프롤린(Proline)이 포함되지 않은 MEM배지 0.8ml를 첨가한 다음 실험군 (유백피 추출물 0.000001% ~ 0.0001% 처리군)을 증류수와 1:2의 비율로 혼합하여 완전히 균질화시켜 5000g에서 10분 동안 원심분리 시켜 상등액을 처리한 다음 14C-Proline(10μCi) 100㎕를 포함한 배양액으로 세포를 배양하였다. 24시간이 경과한 후에 총단백질과 콜라겐 단백질을 측정하였다.Dispense 10 6 cells / well in a 24-well plate and incubate in DMEM medium containing 10% FBS for one day. The next day, replace the medium with fresh medium, incubate for 24 hours, and attach to the bottom with HBSS buffer solution. After washing the cell layer, 0.8ml of MEM medium without serum and proline was added, and then the experimental group (milky skin extract 0.000001% to 0.0001% treated group) was mixed with distilled water at a ratio of 1: 2 and completely homogenized. The supernatant was treated by centrifugation at 5000 g for 10 minutes, and then the cells were incubated with a culture solution containing 100 μl of 14 C-Proline (10 μCi). After 24 hours, total protein and collagen protein were measured.
먼저 세포외 총단백질의 합성량을 측정하기 위하여 각 Well의 배양액을 한쪽 끝을 봉인한 투석관에 넣고 다른쪽 끝을 봉인하여 Cold Buffer (Tris-Hcl 0.05mol/L, NaCl 0.2mol/L, CaCl2 0.05mol/L, Phenylmethylsulfonyl fluoride 0.3mN)로 24시간 투석을 완료한 다음 각각 100㎕를 취하여 Counting Vial에 담아 10ml의 Scintillation cocktail을 넣어 Liquid Scintillation Counter(LSC)로 1분간 방사능을 측정하였다.First, in order to measure the amount of extracellular total protein, the culture medium of each well was placed in a sealed dialysis tube at one end and sealed at the other end of the Cold Buffer (Tris-Hcl 0.05mol / L, NaCl 0.2mol / L, CaCl). 2 0.05mol / L, Phenylmethylsulfonyl fluoride 0.3mN) was completed for 24 hours, and then 100 μl each was added to the Counting Vial and 10 ml of Scintillation cocktail was added to the Liquid Scintillation Counter (LSC) for 1 minute.
세포 내 총 단백질의 합성량을 측정하기 위하여 세포배양액을 제거한 각 Well에 0.1N NaOH 및 Phenylmethylsulfonyl fluoride 0.3mN 를 첨가한 다음 60℃에서 30분 동안 유지하여 세포막을 파괴시킨 후 세포균질액을 한쪽 끝을 봉인한 투석관에 넣고 다른쪽 끝을 봉인하여 Cold Buffer(Tris-Hcl 0.05mol/L, NaCl 0.2mol/L, CaCl2 0.05mol/L, Phenylmethylsulfonyl fluoride 0.3mN)로 24시간 투석을 완료한 다음 각각 100㎕를 취하여 Counting Vial에 담아 10ml의 Scintillation cocktail을 넣어 LSC로 1분간 방사능을 측정하였다.To measure the total amount of protein in the cell, 0.1N NaOH and 0.3mN of Phenylmethylsulfonyl fluoride were added to each well from which the cell culture medium was removed, and then maintained at 60 ° C. for 30 minutes to destroy the cell membrane. Place in a sealed dialysis tube and seal the other end to complete dialysis with Cold Buffer (Tris-Hcl 0.05mol / L, NaCl 0.2mol / L, CaCl 2 0.05mol / L, Phenylmethylsulfonyl fluoride 0.3mN) for 24 hours. 100 μl was taken and placed in Counting Vial. 10 ml of Scintillation cocktail was added and the radioactivity was measured by LSC for 1 minute.
세포내/외 콜라겐 단백질의 합성량을 측정하기 위하여 투석을 완료한 세포배양액 및 세포균질액을 각 각 100㎕ 취하여 1.5ml Microtube에 넣고 콜라겐에이즈 완충 용액(0.05M Tris-Hcl, 1mM CaCl2, 0.3mM Phenylmethylsulfonyl fluoride), 콜라겐에이즈효소(100 ppm) 100㎕를 첨가 한 후에 3시간 동안 37℃에서 유지시켜 Collagen을 완전히 분해시킨 다음에 분해되지 않은 단백질을 제거하기 위하여 50%의 Trichloroacetic acid 및 1% Tannic acid를 함유하는 용액을 500㎕ 첨가한 다음에 4℃에서 30분동안 침전시킨 후에 1000xg에서 5분간 원심분리 시킨 다음에 상등액을 100㎕를 취하여 Counting Vial에 담아 10ml의 Scintillation cocktail을 넣어 LSC로 1분간 방사능을 측정하였다. 이 방사능 측정치로부터 아무것도 처리하지 않은 대조군의 콜라겐 합성량을 100%로 보고 상대적인 콜라겐 합성률을 퍼센트로 나타내었다. <표 2>To measure the amount of intracellular / extracellular collagen protein synthesis, 100 μl of dialysis-produced cell culture solution and cell homogenate were placed in 1.5 ml microtubes, and the collagen buffer solution (0.05 M Tris-Hcl, 1 mM CaCl 2, 0.3). After adding 100 μl of mM Phenylmethylsulfonyl fluoride) and collagenase enzyme (100 ppm), it was maintained at 37 ° C. for 3 hours to completely decompose Collagen, and then remove 50% of Trichloroacetic acid and 1% Tannic to remove undigested protein. After adding 500µl of acid-containing solution, settling at 4 ℃ for 30 minutes, centrifuging at 1000xg for 5 minutes, and then taking 100µl of supernatant into a counting vial, and adding 10ml Scintillation cocktail to LSC for 1 minute. Radioactivity was measured. From the radioactivity measurement, the collagen synthesis amount of the untreated control group was 100%, and the relative collagen synthesis rate was expressed as a percentage. TABLE 2
사람의 섬유아세포의 콜라겐 합성에 대한 효능, 효과를 연구하기 위하여 14C-Proline를 포함한 세포배양액에 본 발명의 유효성분인 유백피추출물을 이상과 같이 처리한 결과, 콜라겐 합성 촉진효과가 유백피추출물의 농도에 따라 상승되는 것으로 나타났다. 특히, 유백피 추출물 0.0001%를 처리한 경우에는 2배 이상 콜라겐 합성률이 증가하였다.In order to study the efficacy and effect on the collagen synthesis of human fibroblasts, the milk culture extract, which is the active ingredient of the present invention, was treated with the cell culture medium containing 14 C-Proline as described above. It appeared to increase with the concentration of. In particular, when treated with 0.0001% of baekpipi extract collagen synthesis rate increased more than two times.
<유백피 추출물의 세포외기질 단백질 합성 촉진에 대한 조직병리학적 실험>Histopathological experiments on the promotion of extracellular matrix protein synthesis of milk extract
조직병리학적 실험을 수행하기 위하여, 생후 42일~56일된 마우스 (C57BL/6, female)를 사용하였다. 피부의 조직병리학적 평가를 위해서는 무모생쥐(Hairless mouse) 를 사용하는 것이 일반적이나, 본 발명의 목적은 두피용 화장료이므로, 정상적인 모발 및 모낭이 존재하는 조건이 실제 사람의 두피 환경와 유사하다고 판단하여, 무모생쥐를 사용하지 아니하였다.To perform histopathological experiments, mice aged 42 to 56 days old (C57BL / 6, female) were used. Hairless mice are generally used for histopathological evaluation of skin. However, since the object of the present invention is cosmetic for scalp, it is determined that the condition of normal hair and hair follicles is similar to the actual human scalp environment. Hairless mice were not used.
먼저 마우스의 등부위의 털을 전기면도기를 이용하여 제거하고 각 마우스의 무게를 재서 몸무게가 골고루 분산이 되도록 5마리씩 나누었다. 하루 동안 적응 기간을 두고 다음날부터 제모 부위에 대조약 및 유백피 추출물을 도포하였으며, 이때 대조약으로는 40% 에탄올을, 시험약으로는 제조예에 따른 유백피추출물의 농축 고형물을 40% 에탄올로 희석하여 사용하였다.First, the hair on the back of the mouse was removed using an electric razor, and each mouse was weighed and divided into 5 pieces so that the weight was evenly distributed. After the adaptation period for one day, the control drug and the milky skin extract were applied to the hair removal site from the next day. At this time, 40% ethanol was used as the control drug and the concentrated solid of the milky skin extract according to the preparation was 40% ethanol. Diluted to use.
마우스 개체당 등부위에 1일 1회, 100 마이크로리터씩을 4주간 도포하였다. 시험 종료 후, 모든 동물은 안락사 시킨 후 부검을 실시하였으며, 등 쪽 피부는 한 마리당 2군데 씩 떼어내어(2 x 2 cm) 필터페이퍼에 편평하게 부착하고, 10% 중성 포르말린에 고정시킨 다음 일반적인 조직처리 과정을 거쳐 파라핀 포매하여 4 마이크로미터 절편을 잘라 H & E (헤마톡실린 & 에오신) 염색, Verhoeff 염색 (엘라스틴 섬유 및 콜라겐 감별)을 실시 하였다. 모든 염색 과정이 끝난 후 시료는 이미지 애널라이져 (Image Analyzer)를 이용하여 진피 층의 두께를 측정하였으며, 세포외기질 구성 단백질인 엘라스틴과 콜라겐의 염색 정도에 따라 이들 단백질의 양을 대조군을 기준으로 상대적인 비율로 나타내어 <표 3>과 같은 결과를 얻었다.100 microliters were applied to the dorsal area per mouse subject for 4 weeks. At the end of the test, all animals were euthanized and necropsied. The dorsal skin was detached 2 per head (2 x 2 cm), attached flat to filter paper, fixed in 10% neutral formalin and then normal tissue. After treatment, paraffin embedding, 4 micrometer sections were cut and subjected to H & E (hematoxylin & eosin) staining, Verhoeff staining (elastine fiber and collagen differentiation). After all the staining process, the samples were measured by using an image analyzer to measure the thickness of the dermal layer. The relative amounts of these proteins were determined based on the degree of staining of the extracellular matrix constituent proteins elastin and collagen. It showed by the ratio and the result similar to <Table 3> was obtained.
< 유백피추출물의 라미닌-10 단백질 발현촉진 효능평가 실험><Evaluation of Laminin-10 Protein Promoting Effect of Milky Skin Extracts>
상 기의 세포 분리/ 배양법과 동일한 방법으로 사람의 피부 섬유아세포를 배양하였다. 세포를 10% FBS가 포함된 DMEM 배지를 이용하여, 1.8 x 106 cell/ml 의 농도로 100mm 배양접시에 10ml씩 넣어주고, 하룻밤을 배양시킨다. 다음날 FBS가 없는 배지로 바꿔준 후, 6시간 후 유백피 추출물을 0.000001% ~ 0.0001%로 처리하고 48시간 배양한다. 48시간 후, 인산완충용액을 이용하여 2번 씻어준다. 미리 준비해 둔, 세포분해 완충용액을 500ul 적용하여 세포를 긁어모은다. 얼음에 20분 방치한 후, 원심분리를 이용하여 상등액만을 취하고, 브래드포드 방법을 사용하여 흡광도를 측정해 총 단백질량을 정량한다. 4~20% 트리스-글리신 에스디에스 페이지 (SDS-PAGE) 젤 2개에, 베타-머캅토에탄올(β-mercaptoethaol) 이 들어간 염료를 넣고 5분간 끓인 단백질을 각 각100ug 로딩하고 전기영동한다. 염료가 젤의 2/3 위치에 오면 전기 영동을 멈추고, 젤을 분리하여 2개의 니트로 셀룰로오즈 멤브레인 (Nitrocellulose membrane)과 3M 페이퍼를 이용하여 100V전압으로 4℃에서 각 각 트랜스퍼(Transfer) 해준다. 1시간 전압을 걸어준 뒤 니트로 셀룰로오즈 멤브레인을 조심스럽게 분리하고, 1% BSA(Bovine Serum Albumin)로 실온에서 1시간 블로킹 시킨다. TTBS(Tween-20 TBS)완충용액으로 멤브레인을 2번 씻어준다. 라미닌-10과 대조군으로 사용할 베타-액틴의 항체가 포함된 용액을 각 각10ml 넣어주고, 멤브레인을 움직여가며 3시간 항원-항체 반응시킨다. TTBS 완충용액으로 빨리 헹구어주고, 형광 물질이 달린 두 번째 항체를 넣어 30분간 반응시킨다. 반응이 끝나면 트리스 완충용액(TBS)으로 두 번 씻어내고, 형광반응을 유도시키는 용액인 ECL 용액을 이용하여 형광 반응시킨다. 노출 시간을 조정하면서, 엑스-레이 필름을 이용하여 형광 반응을 디텍션한다. 필름을 스캔하고, 이미지 마스터 소프트웨어를 이용하여 각 밴드의 밀도를 수치화 한다. 세포 내에서 항상 일정하게 발현된다고 알려진 베타-액틴 단백질의 발현 패턴을 기본 조건으로 하여 수치를 보정하고, 대조군(유백피추출물을 처리하지 않은 조건) 에서 라미닌-10의 발현량을 100%로 보았을 때, 유백피추출물 처리군의 발현량에 대한 상대적인 수치를 <표 4>과 같이 기록하였다.Human skin fibroblasts were cultured in the same manner as the cell isolation / culture method. Using DMEM medium containing 10% FBS, put the cells in a 100mm culture dish at a concentration of 1.8 x 10 6 cells / ml, and incubate overnight. The next day, after changing to a medium without FBS, after 6 hours, the milk extract is treated with 0.000001% to 0.0001% and incubated for 48 hours. After 48 hours, rinse twice with phosphate buffer solution. The cells are scraped by applying 500 ul of cytolysis buffer prepared beforehand. After standing on ice for 20 minutes, only the supernatant is taken by centrifugation, and the absorbance is measured using the Bradford method to quantify the total amount of protein. To two 4-20% Tris-Glycine SDS-PAGE gels, add a dye containing beta-mercaptoethanol (beta-mercaptoethaol) and load 100 ug of each boiled protein for 5 minutes and electrophoresis. When the dye is placed in the 2/3 position of the gel, the electrophoresis is stopped, the gel is separated and transferred at 4 ° C. at 100V voltage using two Nitrocellulose membranes and 3M paper. After applying the voltage for 1 hour, the nitro cellulose membrane is carefully separated and blocked with 1% BSA (Bovine Serum Albumin) for 1 hour at room temperature. Rinse the membrane twice with TTBS (Tween-20 TBS) buffer solution. 10ml each of the solution containing laminin-10 and the beta-actin antibody to be used as a control is added, and the antigen-antibody reaction is carried out for 3 hours while moving the membrane. Rinse quickly with TTBS buffer and add a second antibody with fluorescent material to react for 30 minutes. After the reaction is rinsed twice with Tris buffer (TBS), and fluorescence reaction using ECL solution, a solution that induces fluorescence reaction. While adjusting the exposure time, the fluorescence reaction is detected using an X-ray film. The film is scanned and the density of each band is quantified using the image master software. When the value is corrected based on the expression pattern of beta-actin protein, which is known to be constantly expressed in cells, based on the basic condition, and the expression level of laminin-10 is 100% in the control group (no milk extract). , Relative values for the expression level of the milk extract treatment group was recorded as shown in Table 4.
<표 4>에서 보는 바와 같이 유백피 추출물을 0.000001% ~ 0.0001% 처리 하였을 때, 농도에 비례하여 라미닌-10 단백질 발현율이 증가함을 확인하였다. 이를 통하여 유백피 추출물이 라미닌-10의 발현을 증가시켜, 모낭 조직의 발달 촉진함으로서, 건강한 모근을 유지하는데 유효한 성분임을 입증하였다.As shown in Table 4, when the milk extract was treated with 0.000001% to 0.0001%, it was confirmed that the laminin-10 protein expression rate increased in proportion to the concentration. It was proved that the milky skin extract increased the expression of laminin-10 and promoted the development of hair follicle tissues, thereby being an effective ingredient for maintaining healthy hair roots.
본 발명의 화장료조성물은 액상, 크림상, 페이스트상, 또는 고체상 등의 두피에 적용시킬 수 있는 모든 제형으로 제조가 가능하며, 통상의 첨가제를 가하여 두피케어를 위한 에멀전 타입의 두피로션과 액상의 스킨 및 앰플 타입 등의 조성물로 제조될 수 있으며 이들 제형의 에어졸 타입도 포함한다.The cosmetic composition of the present invention can be prepared in all formulations that can be applied to the scalp, such as liquid, cream, paste, or solid phase, and emulsion type scalp lotion and liquid skin for scalp care by adding conventional additives. And ampule types and the like, and also include aerosol types of these formulations.
본 발명의 유백피 추출물이 사람의 섬유아세포와 동물에서 콜라겐 및 엘라스틴 섬유의 합성을 촉진하는 것을 앞선 평가에서 확인하였다. 또한, 유백피 추출물은 모낭 형성 및 발달에 중요한 인자인 라미닌-10의 발현도 촉진시켰다. 실제, 유백피 추출물을 두피용 화장료조성물에 적용하여 그 조성물이 사람의 두피의 탄력 증진 및 모근 강화에 효능이 있는지를 확인하기 위하여, 다음의 비교예 및 실시예를 바탕으로 임상평가를 실시하였다. 하기 실시예는 본 발명을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예로 한정되는 것은 아니다.It was confirmed in the previous evaluation that the milk extract of the present invention promotes the synthesis of collagen and elastin fibers in human fibroblasts and animals. In addition, the milk extract extract also promoted the expression of laminin-10, an important factor for hair follicle formation and development. Actually, the milky skin extract was applied to the cosmetic composition for scalp to confirm whether the composition is effective in enhancing the elasticity of the human scalp and strengthening the hair root, and clinical evaluation was performed based on the following comparative examples and examples. The following examples are merely illustrative of the present invention, and the scope of the present invention is not limited to the following examples.
<두피 탄력성 증가에 대한 임상평가>Clinical Evaluation of Increased Scalp Elasticity
건강한 25 ~ 35세 남녀 피험자 20 명을 5명씩 4군으로 나누어 각 각 <표 5>의 비교예 및 실시예의 조성물을 2개월 사용하게 한 후, 피부 탄력을 측정하였다. 탄력 측정은 온도 25℃, 습도 75%가 유지되는 항온, 항습실에서 피부탄력측정기 (Cutometer SM575, C+K Electronic Co., 독일) 를 이용하여 실시하였으며, 피부 탄력은 ΔR2 값으로 나타내는데, 이 값은 피부의 탄력성 (Elasticity)을 나타내어, 수치가 클수록 피부탄력성이 증가하였음을 의미한다. <표 6>20 healthy 25-35 year old male and female subjects were divided into 4 groups of 5 people each, and the composition of the Comparative Examples and Examples of <Table 5> was used for 2 months, and skin elasticity was measured. The elasticity measurement was carried out using a skin elasticity measuring instrument (Cutometer SM575, C + K Electronic Co., Germany) in a constant temperature and humidity room maintained at a temperature of 25 ℃, humidity 75%, the skin elasticity is expressed as ΔR2 value, The elasticity of the skin (elasticity) is indicated, which means that the higher the skin elasticity is increased. TABLE 6
<표6>에서 보는 바와 같이 비교예의 경우에는 탄력성이 크게 증가하지 않은데 비해, 유백피 추출물을 함유하고 있는 실시예의 경우에는 탄력성이 증가하였다.As shown in Table 6, in the comparative example, the elasticity did not increase significantly, whereas in the example containing the milky skin extract, the elasticity increased.
특히, 유백피 추출물 이외에 보습제, 피지조절제, 항염증제 등의 보조성분이 함유되었을 때, 탄력성이 보다 더 증가하여 우수한 조성물이 되는 것을 확인하였다.In particular, when it contains an auxiliary component such as a moisturizer, sebum control agent, anti-inflammatory agent in addition to the milk extract, it was confirmed that the elasticity is further increased to become an excellent composition.
< 모근 강화 효과에 대한 임상평가><Clinical Evaluation of Hair Root Strengthening Effect>
유백피 추출물의 모근 강화 효과를 검증하기 위하여 두발 당겨보기 검사를 실시하였다. 두발 당겨보기는 피부과학(개정 4판), 제25장 모발질환, p.476-477 에서 모발주기 이상을 진단할 수 있는 방법으로 소개된 평가법으로 본 발명에서는 모근 강화 정도를 판단하기 위하여 실시하였다. 두피 탄력성 시험에 참가하였던 피험자들을 대상으로 피험자의 머리를 고정시키고 인장강도 시험기( Zwicki 1120) 의 load cell에 모발 한 가닥을 걸어, 21.5 gmf (성장기 모발의 두피가 당겨져 올라오는 힘의 평균치)의 힘으로 모발을 잡아당겼다. 한 사람당 50개의 머리카락 (전두부, 두정부, 양 쪽 측두부, 후두부 등 5개 부위에서 각 각10가닥)을 잡아당겨, 뽑히는 모발의 개수를 세어, 1인당 빠지는 모발수의 평균값을 얻었다. 비교예의 경우에서는 사용 전, 후 큰 차이가 없었으나, 실시예의 경우에는 사용 후 빠지는 모발의 개수가 현저히 감소하여 모근이 강화되었음을 확인하였다. <표 7>A hair pull test was conducted to verify the hair root strengthening effect of the milk extract. Pulling the hair is an evaluation method introduced as a method for diagnosing hair cycle abnormality in dermatology (Rev. 4), Chapter 25 Hair Disease, p.476-477. . The subjects who participated in the scalp resilience test were to fix the subject's head and hang a strand of hair in the load cell of the tensile strength tester (Zwicki 1120) to obtain a force of 21.5 gmf (average value of the force of the growing scalp's scalp). Pulled the hair down. 50 hairs per person (10 strands each from five sites including the frontal, head and two temporal and posterior heads) were pulled and the number of hairs pulled out was counted to obtain the average number of hairs lost per person. In the case of the comparative example, there was no significant difference before and after use, but in the case of the example, the number of hairs falling out after use was significantly reduced, thereby confirming that the hair root was strengthened. TABLE 7
상기 결과를 종합하여 보면, 본발명의 유백피 추출물은 사람의 피부 세포에서 콜라겐에이즈 효소 억제와 콜라겐 합성 촉진 효과가 매우 우수하였으며, 실제 동물 평가에서도 진피층이 두꺼워 지는 것을 확인하였다. 또한, 모낭 조직의 발달을 촉진시키는 인자인 라미닌-10의 단백질 발현을 촉진하였으며, 두피 탄력 증진 및 모근 강화 효능에 대한 임상평가에서도 우수한 효과를 나타내었다.In summary, the milk extract of the present invention was very effective in inhibiting collagenase enzyme and promoting collagen synthesis in human skin cells, and also confirmed that the dermal layer was thickened in actual animal evaluation. In addition, it promoted the protein expression of laminin-10, a factor that promotes the development of hair follicle tissue, and showed an excellent effect in clinical evaluation of scalp elasticity enhancement and hair root strengthening efficacy.
본 발명은 유백피 추출물을 함유하는 화장료 조성물에 관한 것이다. 더욱 구체적으로 본 발명은 유효성분으로서 콜라겐 단백질을 분해하는 콜라겐에이즈(Collagenase) 효소의 활성을 억제시킴과 동시에 콜라겐 단백질 합성을 촉진시키는 효과를 갖는 유백피 추출물을 함유한 것을 특징으로 하는 두피화장료 조성물에 관한 것으로, 본 발명에 따르는 유백피 추출물은 부작용이 거의 없고, 콜라겐에이즈 억제 및 콜라겐 합성 촉진에 따라 두피탄력 증진 및 라미닌-10발현 촉진으로 인한 모근강화로 두피의 노화를 방지하는 효과가 있다. The present invention relates to a cosmetic composition containing the milk extract. More specifically, the present invention provides a scalp cosmetic composition comprising a milky skin extract having the effect of inhibiting the activity of the collagenase (Collagenase) enzyme that breaks down the collagen protein as an active ingredient and promoting collagen protein synthesis. Related to the present invention, the milk extract of the milk extract has almost no side effects, and has the effect of preventing aging of the scalp by strengthening the hair root due to the enhancement of scalp elasticity and the promotion of laminin-10 expression according to the inhibition of collagenase and the promotion of collagen synthesis.
Claims (4)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050016084A KR20060094704A (en) | 2005-02-25 | 2005-02-25 | Cosmetic composition containing collagenase inhibition and collagen synthesis promoting effect containing milk extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020050016084A KR20060094704A (en) | 2005-02-25 | 2005-02-25 | Cosmetic composition containing collagenase inhibition and collagen synthesis promoting effect containing milk extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20060094704A true KR20060094704A (en) | 2006-08-30 |
Family
ID=37602441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020050016084A Withdrawn KR20060094704A (en) | 2005-02-25 | 2005-02-25 | Cosmetic composition containing collagenase inhibition and collagen synthesis promoting effect containing milk extract |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20060094704A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190053634A (en) * | 2017-11-10 | 2019-05-20 | 남부대학교산학협력단 | Composition having antibacterial activity for pityrosporum |
-
2005
- 2005-02-25 KR KR1020050016084A patent/KR20060094704A/en not_active Withdrawn
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190053634A (en) * | 2017-11-10 | 2019-05-20 | 남부대학교산학협력단 | Composition having antibacterial activity for pityrosporum |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20100135871A (en) | Active ingredient that stimulates proliferation and / or activity of fibroblasts | |
| KR101064904B1 (en) | Cosmetic composition for improving acne comprising a natural extract | |
| US8557795B2 (en) | Composition containing Chamaecyparis obtusa polysaccharides to be externally applied to the skin | |
| US20130101689A1 (en) | Composition containing paper mulberry extracts | |
| CA2139253C (en) | Skin external agent | |
| US6193975B1 (en) | Use of potentilla erecta extract in the cosmetic and pharmaceutical field | |
| EP2612654A2 (en) | Cosmetic composition for improving skin elasticity | |
| JP2011088845A (en) | Involucrin expression inhibitor | |
| KR101917645B1 (en) | Cosmetic composition comprising saccharomyces ferment filtrate, asparagus officinalis stem extract and tussilago farfara flower extract | |
| KR19990086516A (en) | Anti-aging cosmetic composition containing ginseng extract | |
| KR101939112B1 (en) | Composition of skin external application containing ginsenoside F1 | |
| KR20140018666A (en) | Composition for skin external application containing fermented soybean extract | |
| KR20080093500A (en) | Roe deer urine extract | |
| JPH03112912A (en) | Cosmetic composition | |
| KR101909533B1 (en) | Composition of skin external application containing ginsenoside F1 | |
| KR101322850B1 (en) | The cosmetic composition for pore-minimizing and inhibition of Sebum Secretion containing the extract of leaves of Mentha arvensis var. piperascens, wheat bud, and Platycodon grandiflorum | |
| KR20170045927A (en) | Anti-aging composition for skin external application comprising Potentilla chinensis Extract and Method for Preparing the Same | |
| JP2008088075A (en) | Profilaggrin/filaggrin production promoter, epidermal keratinocyte proliferation promoter, skin care preparation for normalizing epidermis/horny cell layer, profilaggrin/filaggrin production-promoting method and epidermal keratinocyte proliferation-promoting method | |
| KR20230140853A (en) | A scalp and hair care composition comprising acetyl Hexapeptide-8 | |
| JP2002284648A (en) | Hair restorer composition | |
| KR102027349B1 (en) | Composition of skin external application containing polysaccharides, and the method for preparing thereof | |
| KR20060094704A (en) | Cosmetic composition containing collagenase inhibition and collagen synthesis promoting effect containing milk extract | |
| KR101131488B1 (en) | Skin care compositions for antiwrinkle effect | |
| KR20180108255A (en) | Composition for skin improvement containing parishin B | |
| JP7411196B2 (en) | Type XVII collagen maintenance and enhancement agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20050225 |
|
| PG1501 | Laying open of application | ||
| PC1203 | Withdrawal of no request for examination | ||
| WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |